Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.48 |
| ▸ | GRB2 | P62993 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 4/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.44 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.44 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13196227 | 0.94 | TLR2 (0.45) | PTPN1SIRT5KMT2A | |
| SCHEMBL13311052 | 0.94 | TLR2 (0.45) | PTPN1SIRT5KMT2A | |
| SCHEMBL29371674 | 0.94 | TLR2 (0.45) | PTPN1SIRT5KMT2A | |
| SCHEMBL23477323 | 0.91 | TLR2 (0.45) | PTPN1KMT2A | |
| SCHEMBL30895476 | 0.90 | PTPN1 (0.51) | PTPN1GRB2SIRT5 | |
| SCHEMBL15674187 | 0.89 | PTPN1 (0.49) | PTPN1 | |
| SCHEMBL2734926 | 0.88 | PTPN1 (0.47) | PTPN1SIRT5 | |
| SCHEMBL12972289 | 0.88 | PTPN1 (0.47) | PTPN1SIRT5 | |
| SCHEMBL13225452 | 0.88 | TLR2 (0.49) | PTPN1 | |
| SCHEMBL13696901 | 0.88 | TLR2 (0.49) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3030244-B1 | POLYCONJUGATES FOR DELIVERY OF RNAI TRIGGERS TO TUMOR CELLS IN VIVO | ARROWHEAD PHARMACEUTICALS INC (US) | 2021-04-21 | — | — | EP | disclosed |
| US-20170022497-A1 | Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo | Arrowhead Pharmaceuticals, Inc. | 2017-01-26 | — | — | US | disclosed |
| US-9487556-B2 | Polyconjugates for delivery of RNAi triggers to tumor cells in vivo | Arrowhead Pharmaceuticals, Inc. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9487556-B2 | Polyconjugates for delivery of RNAi triggers to tumor cells in vivo | Arrowhead Pharmaceuticals, Inc. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20150045573-A1 | Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo | Arrowhead Pharmaceuticals, Inc. | 2015-02-12 | — | — | US | disclosed |
| US-20150045573-A1 | Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo | Arrowhead Pharmaceuticals, Inc. | 2015-02-12 | — | — | US | disclosed |
| WO-2015021092-A1 | POLYCONJUGATES FOR DELIVERY OF RNAI TRIGGERS TO TUMOR CELLS IN VIVO | ARROWHEAD RESEARCH CORPORATION (US) | 2015-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022497-A1 | Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo | PAM, PLAUR, M6PR | PTPN1 4013/4885GRB2 3140/4885KDM1A 720/4885 |
| US-20150045573-A1 | Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo | PAM, PLAUR, M6PR | PTPN1 4013/4885GRB2 3140/4885KDM1A 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.